OBJECTIVE: To determine the prevalence of a negative insulinogenic index (change in plasma insulin/change in plasma glucose from 0 to 30 min) from an oral glucose tolerance test according to glucose tolerance category. MATERIALS AND METHODS: Data from the San Antonio Heart Study (n=2494), Japanese American Community Diabetes Study (JACDS; n=594) and Genetics of NIDDM Study (n=1519) were examined. Glucose tolerance was defined by ADA criteria. RESULTS: In the combined cohort, the prevalence of a negative insulinogenic index was significantly higher in diabetes 20/616 (3.2%) compared to normal glucose tolerance 43/2667 (1.6%) (p<0.05). Longitudinally, in the JACDS cohort, the prevalence did not change from baseline (3/594; 0.5%) to 5 (4/505; 0.7%) and 10 years (8/426; 1.9%) (p=0.9) and no subject had a repeat negative insulinogenic index. CONCLUSIONS: A negative insulinogenic index occurs at a low prevalence across glucose tolerance categories although more often in diabetes, but without recurrence over time.
OBJECTIVE: To determine the prevalence of a negative insulinogenic index (change in plasma insulin/change in plasma glucose from 0 to 30 min) from an oral glucose tolerance test according to glucose tolerance category. MATERIALS AND METHODS: Data from the San Antonio Heart Study (n=2494), Japanese American Community Diabetes Study (JACDS; n=594) and Genetics of NIDDM Study (n=1519) were examined. Glucose tolerance was defined by ADA criteria. RESULTS: In the combined cohort, the prevalence of a negative insulinogenic index was significantly higher in diabetes 20/616 (3.2%) compared to normal glucose tolerance 43/2667 (1.6%) (p<0.05). Longitudinally, in the JACDS cohort, the prevalence did not change from baseline (3/594; 0.5%) to 5 (4/505; 0.7%) and 10 years (8/426; 1.9%) (p=0.9) and no subject had a repeat negative insulinogenic index. CONCLUSIONS: A negative insulinogenic index occurs at a low prevalence across glucose tolerance categories although more often in diabetes, but without recurrence over time.
Authors: R L Hanson; R E Pratley; C Bogardus; K M Narayan; J M Roumain; G Imperatore; A Fagot-Campagna; D J Pettitt; P H Bennett; W C Knowler Journal: Am J Epidemiol Date: 2000-01-15 Impact factor: 4.897
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: W Y Fujimoto; D L Leonetti; J L Kinyoun; L Newell-Morris; W P Shuman; W C Stolov; P W Wahl Journal: Diabetes Date: 1987-06 Impact factor: 9.461
Authors: James B Meigs; Ken Williams; Lisa M Sullivan; Kelly J Hunt; Steven M Haffner; Michael P Stern; Clicerio González Villalpando; Jessica S Perhanidis; David M Nathan; Ralph B D'Agostino; Ralph B D'Agostino; Peter W F Wilson Journal: Diabetes Care Date: 2004-06 Impact factor: 19.112
Authors: Steven E Kahn; John M Lachin; Bernard Zinman; Steven M Haffner; R Paul Aftring; Gitanjali Paul; Barbara G Kravitz; William H Herman; Giancarlo Viberti; Rury R Holman Journal: Diabetes Date: 2011-03-17 Impact factor: 9.461
Authors: Suzanne Filteau; George PrayGod; Andrea M Rehman; Robert Peck; Kidola Jeremiah; Rikke Krogh-Madsen; Daniel Faurholt-Jepsen Journal: Am J Clin Nutr Date: 2021-06-01 Impact factor: 7.045